IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company’s rapid test for bladder cancer.
Read the press release here (in swedish)
IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company’s rapid test for bladder cancer.
Read the press release here (in swedish)
Result from a new German multicenter study At this years EAU (European Association of Urology) meeting in Munich, March 11-15, a German multi-center study on UBC® Rapid was presented. Responsible for the study was Dr Thorsten Ecke, Helios Hospital,...
Evaluation of bladder cancer with point-of-care (POC) tests depends on the detection of bladder cancer associated proteins in urine samples. Common rapid tests for the early detection of bladder cancer are limited to simple positive or negative results and some of...